In vitro characterization of porcine hepatocyte function.
The clinical consequences of acute liver failure are associated with high mortality. Intensive medical intervention is required to treat the symptoms of liver failure, including coagulopathy, metabolic instability, and encephalopathy. Providing temporary liver support with an extracorporeal liver assist device could stabilize the patient until a donor liver became available or the patient's own liver was able to recover. The use of human hepatocytes as the biologic component of the assist device is precluded by the scarcity of available tissue and the limited proliferative potential of adult hepatocytes in vitro. Consequently, porcine hepatocytes are being evaluated as a cell source for liver assist devices. Maintaining differentiated function in isolated hepatocytes, however, remains a challenge in the development of this technology and is complicated by the fact that the key therapeutic functions for short-term survival have not been well defined. Several approaches have been effective in prolonging rodent hepatocyte function in vitro, including manipulation of extracellular matrix. Here, we have investigated porcine hepatocyte function in vitro with a specific emphasis on the response to exogenous collagen matrix. In control cultures, albumin secretion increased during the first 7-10 days of culture to an average of 50 +/- 17 microg/day/10(6) cells and then decreased over the next 2 weeks. The pattern of urea synthesis was slightly different in that it was highest in the first 1-3 days postisolation (140 +/- 19 microg/day/10(6) cells) and then decreased by about 50% to a plateau level that was stable during the next 3-4 weeks of culture. Cytochrome P450-mediated activities were the most labile with time in culture and were undetectable after the first week in the absence of pharmacological inducers. In contrast to results reported for rat cells, porcine hepatocytes exhibited differentiated function in the absence of any modification of the culture dish surface and function was not increased or prolonged in the presence of exogenous collagen.
Gregory
P G
PG
Organogenesis, Inc., Canton, MA 02021, USA.
Connolly
C K
CK
Toner
M
M
Sullivan
S J
SJ
D000418:Albumins / Q000378:metabolism; D000779:Anesthetics, Local / Q000493:pharmacokinetics; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D018929:Cell Culture Techniques / Q000379:methods*; D002470:Cell Survival / Q000187:drug effects; D017690:Cell Transplantation; D002478:Cells, Cultured; D003094:Collagen / Q000494:pharmacology; D003374:Coumarins / Q000493:pharmacokinetics; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016326:Extracellular Matrix Proteins / Q000494:pharmacology; D005782:Gels; D008012:Lidocaine / Q000493:pharmacokinetics; D008099:Liver / Q000166:cytology* / Q000201:enzymology / Q000378:metabolism; D017114:Liver Failure, Acute / Q000601:surgery*; D010634:Phenobarbital / Q000494:pharmacology; D013552:Swine; D014508:Urea / Q000378:metabolism; D019324:beta-Naphthoflavone / Q000494:pharmacology
D000418:Albumins; D000779:Anesthetics, Local; D000927:Anticonvulsants; D003374:Coumarins; D004791:Enzyme Inhibitors; D016326:Extracellular Matrix Proteins; D005782:Gels; C017299:7-ethoxycoumarin; D019324:beta-Naphthoflavone; D014508:Urea; D003094:Collagen; D003577:Cytochrome P-450 Enzyme System; D008012:Lidocaine; D010634:Phenobarbital